Amgen’s (AMGN) stock has declined 12.1% in the past month. Late last month, Amgen announced the much-awaited 52-week top-line data from a phase II study on MariTide, its GLP-1 therapy being developed for obesity and related conditions. The data showed that MariTide led to sustainable weight loss, robust and clinically meaningful improvements in cardiometabolic parameters and a strong reduction of average blood sugar levels.However, despite the encouraging data, Amgen’s stock has declined as the weight loss ...